GLP1Meter
Home / Side effects

Hair loss from GLP-1

You are dealing with a symptom and want to know if it is expected.

Reference and calculator, not medical advice. Dosing figures below are transcribed from FDA-approved prescribing information and link back to it. Last reviewed August 2026.

Whether hair loss is documented for the medication you are on depends entirely on which one it is — and the difference between products is much larger than most coverage of this topic suggests.

What each label actually reports

Incidence figures come from the adverse-reaction sections of the prescribing information. The two weight-management products report trial data; the diabetes products list alopecia only as a postmarketing report.

ProductReported inWomenMen
Wegovy SemaglutideClinical trials4%0.9%
Zepbound TirzepatideClinical trials7.1%0.5%
Ozempic SemaglutidePostmarketing reports onlyno denominatorno denominator
Mounjaro TirzepatidePostmarketing reports onlyno denominatorno denominator
Rybelsus Semaglutide (oral)Postmarketing reports onlyno denominatorno denominator
Saxenda LiraglutidePostmarketing reports onlyno denominatorno denominator
Trulicity DulaglutidePostmarketing reports onlyno denominatorno denominator

A postmarketing entry means the reaction has been reported after approval but the label gives no rate, because spontaneous reports have no denominator. It is not evidence that the rate is lower — only that it was not measured. Every figure above is checked against the label linked at the foot of this page.

Only the two weight-management products carry trial figures. Wegovy reports 3.3% at its 2.4 mg dose against 1% on placebo; Zepbound reports 7.1% in women and 0.5% in men. The five products indicated primarily for type 2 diabetes list alopecia only as a postmarketing report — meaning it has been reported since approval, but without a rate, a denominator or a comparison group.

Reading that as "the diabetes ones are safer for hair" would be a mistake. A postmarketing entry records that something was reported, not how often it happens. The two categories were measured differently and cannot be ranked against each other.

Listed in the prescribing information

Common adverse reactions listed for GLP-1 receptor agonists as a class.

These products carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Read the full prescribing information for your specific product and discuss it with your prescriber — this summary is not complete and is not a substitute for that document.

Common questions

I am on Ozempic — is my hair loss on the label?
Alopecia appears in the Ozempic postmarketing section, so it has been reported. There is no incidence figure, so the label cannot tell you how common it is. The label link at the foot of this page goes straight to the document.
Does switching products change this?
Nothing in the labels supports predicting that, and switching is a prescriber decision made on grounds that have little to do with hair. The two products with trial data are also the two that produce the most weight loss.
Is compounded semaglutide different?
A compounded preparation has no label of its own and no trial data. What you can reason about is the active ingredient and the dose, using the branded label as the reference point.

Sources and last review

Every dosing figure on this page is transcribed from an FDA-approved label and links back to it. Conversions are arithmetic you can repeat by hand. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.

Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.

Related